The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi bubbles2,
yes, that’s the consensus of opinion from the experts, in relation to Covid the Foralumab phase 1 results should be similar for any Covid variant or other serious respiratory disease. That’s because Foralumab is preventing/reducing the cytokine storm, which is where the body’s own immune system goes haywire and results in massive damage to the lungs/airways. It’s the rapid destruction of cells in the airway that clog up and damage the lungs and result in increasingly dangerously lower and lower levels of oxygen in the blood. This new method of anti-inflammation can also be targeted to different areas: nasally/inhalation to treat the airways as for other respiratory viruses/diseases, nasally to cross the brain barrier for the various brain diseases, e.g. Alzheimer’s, and orally to target the small intestine for digestive diseases like Crohn’s and IBS. The possibility for much more effective and less toxic treatment for so many different illnesses, and also to use this targeted dosing for other monoclonal antibody drugs (by other companies on a royalty basis due to the TILS patent) is simply a breathtaking proposition, in my opinion.
i’m sorry if this is stating the obvious but just want to clarify - i’m not very scientifically minded haha, so foralumab is essentially effective against any mutation?
oh, i'm so sorry to appear really stupid, I just saw mab and assumed it was relevant and a positive thing if theirs weren't succeeding - but thank you for that informaiton its very helpful :)
Plan & Mike,
Nice posts.
vbw
Spot on MikeSM.
Bubbles, I know the Guardian article isn't talking about vaccines - what it is referring to is a monoclonal antibody that is, quote "specifically engineered to target the virus", and the mutations appear to prevent them adhering to the coronavirus spikes which render them less effective.
Foralumab's monoclonal antibody DOES NOT TARGET THE VIRUS. It works by preventing the body's immune system from attacking itself as well as attacking the invading virus, the cause of extreme illness and death, and it is therefore irrelevant what mutation has infected the patient.
As a Tiziana investor it is vital to recognise that any failure of a totally different type of drug such as Regeneron must not be confused with Foralumab since inaccurate, negative comments can only be harmful to our interests.
the report isnt talking about vaccines though, it’s talking about antibodies .. although it’s an old article i thought it was worth knowing that gsk eli lilly and regeneron treatments all have not been entirely successful
The Guardian report isn't relevant to Tiziana's Foramulab monoclonal antibody. This isn't a vaccine, but a drug that works by preventing the body's immune system from overproducing the 'T' cells that naturally attack the virus but can, when uncontrolled, also attack the cell structure of the host's own lungs causing extreme illness and death.
The initial results released after the Phase I trial in Brazil indicated that the Foramulab monoclonal antibody was highly effective in moderating the body's production of 'T' cells and thereby appeared to significantly improve the outcome for Covid patients. We are all awaiting an announcement regarding Phase II trials that will hopefully replicate the Phase I findings and lead to Foramulab being a valuable early treatment for those suffering from the Covid virus, regardless of strain.... The announcement of Phase II Covid trials and the IPO of Accustem will surely create a strong bounce in the share price. May I suggest that for TILS shareholders patience will prove to be a worthwhile virtue...